Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Mantle-Cell
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Mantle-Cell
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, Mantle-Cell
Description
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1). MeSH
Hierarchy View
Phase 2 Indicated Drugs (104)
allogeneic natural killer cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes
autologous mononuclear stem cell
cpg-activated, autologous tumor vaccine
hyaluronidase (human recombinant) (Hylenex)
Phase 1 Indicated Drugs (109)
allogeneic gamma-delta t cells
anti-cd19-car cmv-specific t-lymphocytes
anti-cd20 b9e9 scfv-streptavidin fusion protein
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
bcl-2 antisense oligonucleotide
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes
Other Experimental Indicated Drugs (13)
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (39)
Blood and Marrow Transplant Clinical Trials Network
ECOG-ACRIN Cancer Research Group
European Mantle Cell Lymphoma Network
French Innovative Leukemia Organisation
German Low Grade Lymphoma Study Group
Gruppo Italiano Studio Linfomi
HOVON - Dutch Haemato-Oncology Association
Organization Involved with Phase 2 Indications (201)
Academic and Community Cancer Research United
All India Institute of Medical Sciences
Australasian Leukaemia and Lymphoma Group
Badalona Hospital Germans Trias i Pujol
Beijing InnoCare Pharma Tech Co., Ltd.
British Columbia Cancer Agency
Cancer Care Centers of South Texas , San Antonio
Cancer Care Clinic and Hospital, Nagpur, India
Cantonal Hospital of St. Gallen
Case Western Reserve University
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
City of Hope National Medical Center
Consortium for Improving Survival of Lymphoma
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Henan University of Traditional Chinese Medicine
Hospital Dr. Jose Molina Orosa
Icahn School of Medicine at Mount Sinai
Istituto Nazionale per lo Studio e la Cura dei Tumori
Jaslok Hospital and Research Centre, Mumbai, India
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Malabar Institute of Medical Sciences
Meenakshi Ammal Dental College and Hospital
Memorial Sloan-Kettering Cancer Center
North Central Cancer Treatment Group
Oregon Health and Science University
Ospedale Maggiore Azienda Sanitaria Universitaria Trieste Ematologia
People's Liberation Army of China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Polish Lymphoma Research Group
Rajiv Gandhi University of Health Sciences
Southern Europe New Drug Organization (SENDO)
State University of New York, Buffalo
Technical University of Munich
The Leukemia and Lymphoma Society
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
University of California, San Diego
University of California, San Francisco
University of Las Palmas de Gran Canaria
University of Medicine and Dentistry of New Jersey
University of Southern California
University of Texas at Houston
Organization Involved with Phase 1 Indications (42)
Organization Involved with Other Experimental Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.